Navigation Links
Alexza Pharmaceuticals Files Shelf Registration Statement
Date:5/4/2010

MOUNTAIN VIEW, Calif., May 4 /PRNewswire-FirstCall/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has filed a universal shelf registration statement with the Securities and Exchange Commission (SEC) that, if declared effective by the SEC, will allow the Company to sell, from time to time, up to $75 million of its common stock, preferred stock, debt securities and/or warrants, either individually or in units, in one or more offerings.  As of the date of this release, the Company has no specific plans to offer the securities covered by the registration statement and the Company is not required to offer the securities in the future pursuant to the registration statement.  The terms of any offering under the registration statement will be established at the time of the offering.  Proceeds from the sale of any securities will be used for the purposes described in a prospectus supplement filed at the time of an offering.  The universal shelf registration statement is intended to provide Alexza Pharmaceuticals with flexibility to raise funds from the offering of its securities in one or more offerings, subject to market conditions and the Company's capital needs.

A shelf registration statement relating to these securities was filed today with the SEC but has not yet become effective.  The securities offered by the Company pursuant to the registration statement may not be sold, nor may offers to buy the securities be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the securities in any jurisdiction in which such offer, solicit
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Mass. , July 24, 2014   ndd ... function testing (PFT) employing precise ultrasound technology, announced that ... the instrument to measure Carbon Monoxide Diffusing Capacity (DLCO) ... the most comprehensive study of Chronic Obstructive Pulmonary Disease ... cause of death in the U.S. and affects millions ...
(Date:7/23/2014)... N.Y. , July 23, 2014 ... of idelalisib to treat patients with relapsed chronic ... lymphocytic lymphoma (SLL) is a significant advance for ... Idelalisib, which goes by the trade name Zydelig®, ... protein that is highly expressed in many B-cell ...
(Date:7/23/2014)... MOUNTAIN VIEW, Calif. , July 23, 2014 ... translational preclinical research, today unveiled their new logo and ... transformation of Surpass, corporate culture to one where our ... This press release comes on the heels of the ... to the Silicon Valley Team:  David Craig, a veteran ...
Breaking Medicine Technology:EasyOne Pro from ndd Medical Technologies Chosen Again as the Exclusive PFT Testing Technology in Phase 2 of COPDGene Study 2The Leukemia & Lymphoma Society Applauds FDA's Approval of Idelalisib To Treat Three Types of Blood Cancers 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 2SURPASS Launches New Company Logo and Corporate Website, Symbolizing Transformation of Company Culture to Meet the Changing Needs of Clients in the Life Science Community Today. 3
... Feb. 15 Intra-Cellular Therapies, Inc. (ITI),announced ... its,first-in-class dual 5HT2A receptor antagonist/dopamine receptor,phosphoprotein modulator ... ITI,s family of compounds that inhibit a ... dysfunction in schizophrenia. Data,characterizing the pharmacological profile ...
... Plan Also Calls for Expansion of Business Development, Streamlining of ... ... Conference Call/Webcast at 11 a.m. EST Today -, LA JOLLA, Calif., ... strategic plan for 2008 with a focus,on clinical development activities to maximize ...
Cached Medicine Technology:Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 2Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 3Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders 4TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 2TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 3TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 4TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 5TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds 6
(Date:7/24/2014)... 6 Minutes to Skinny focuses on ... high gear with only a few minutes each day ... or lifestyle. This has caught the attention of HealthyandFitZone.com’s ... 6 Minutes to Skinny review shows that Craig ... understand exactly how your body responds to food and ...
(Date:7/24/2014)... ReNewLifeCleansing.com was inspired by ReNew Life ... “makeover.” While waging her battle with poor health, she ... for her recovery. She became an expert on cleansing, ... herbs, minerals, and other ingredients derived from nature help ... unwanted waste and toxins for better overall health. , ...
(Date:7/24/2014)... 24, 2014 The Republic of Tea, leading ... CARDAMOM CRÈME BRÛLÉE TEA to celebrate “The Hundred-Foot Journey,” a ... and Juliet Blake. A hundred-foot journey begins in the moment ... into a new realm that is far out of your ... physical distance that materially changes the course of your life ...
(Date:7/24/2014)... After waiting two years for her agonizing neck pain ... it was time to get her life back as she ... intervention was needed to bring her true relief. After diligent ... Center for help. Each staff member involved in her introduction ... Montana, the connection and security this Florida team created for ...
(Date:7/24/2014)... 2014 Debt Management Credit Counseling ... organization (DMCC), announced today that it is providing ... student loan borrowers identify and implement affordable repayment ... repayment options to borrowers who are struggling to ... the corresponding repayment terms, depend on many economic ...
Breaking Medicine News(10 mins):Health News:6 Minutes to Skinny: Review Examining Craig Ballantyne’s Weight Loss Program Released 2Health News:6 Minutes to Skinny: Review Examining Craig Ballantyne’s Weight Loss Program Released 3Health News:ReNew Life Launches New Educational Cleansing & Detox Website—ReNewLifeCleansing.com 2Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 2Health News:The Republic of Tea Unveils New Tea Inspired by “The Hundred-Foot Journey” 3Health News:Nonprofit Debt Management Credit Counseling Providing Low Cost Student Loan Help 2Health News:Nonprofit Debt Management Credit Counseling Providing Low Cost Student Loan Help 3
... , WEDNESDAY, Dec. 8 (HealthDay News) -- ... of developing several invasive bacterial diseases, according to a ... found to be especially strong for children 6 years ... the risk for invasive meningococcal disease, the analysis found, ...
... 8, 2010) Jeffrey S. Upperman, MD, director of ... a call to action for filling a significant gap in ... the framework for a pediatric applied trauma research network (PATRN). ... Journal of Pediatric Surgery and the Journal ...
... breakthrough? See what the experts have to say ... Perspectives on Psychological Science . Neuroimaging: ... Special Section on fMRI ( http://pps.sagepub.com/content/5/6/714.full ) ... widespread interest following the publication of Vul et ...
... , WEDNESDAY, Dec. 8 (HealthDay News) -- The children ... pregnancy are less likely to develop atopic dermatitis in their ... Atopic dermatitis (also called atopic eczema) is a chronic and ... The condition affects up to 20 percent of children in ...
... , WEDNESDAY, Dec. 8 (HealthDay News) -- A new ... blood to scan the genome of a fetus may offer ... genetic diseases, a new study suggests. Currently, a sample ... amniocentesis or chorionic villus sampling, both of which pose a ...
... ANN ARBOR, Mich. Patients who have complications after ... even when it is clearly recommended for their diagnosis, ... Cancer Center finds. In addition, patients with complications ... chemotherapy delayed for more than 120 days after diagnosis ...
Cached Medicine News:Health News:Trauma surgeon leads call to action for pediatric applied trauma research network 2Health News:fMRI special section of Perspectives on Psychological Science 2Health News:fMRI special section of Perspectives on Psychological Science 3Health News:Surgery complications linked to chemotherapy delay, U-M study finds 2
Each handle is designed to fit a specific trephine size....
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
... of German Craftsmanship have ... instrumentation in the world. ... available to you! Only ... Meisterbrief certificate, which requires ...
Medicine Products: